ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $6.56M

      Shares

      1.99M

      % of Portfolio

      0.00%

      Average Buy Price

      $13.1

      Avg closing price
      Price range

      21 PRIMECAP Management Health Catalyst Trades

      PRIMECAP Management's position in Health Catalyst is currently worth $6.56M. That's 0.00% of their equity portfolio (275th largest holding). The investor owns 2.75% of the outstanding Health Catalyst stock. The first Health Catalyst trade was made in Q2 2020. Since then PRIMECAP Management bought shares sixteen more times and sold shares on four occasions. The investor's estimated purchase price is $26.1M, resulting in a loss of 75%.

      Avg closing price
      Price range
      Sold 0.9% shares (-18.4k shares) Q2 2025
      Avg closing price $3.92
      Price range $3.58 - $4.52
      Increased shares by 3.8% (+72.5k shares) Q1 2025
      Avg closing price $5.33
      Price range $3.97 - $7.42
      Sold 19.6% shares (-472k shares) Q4 2024
      Avg closing price $7.95
      Price range $6.90 - $9.02
      Increased shares by 1.1% (+25k shares) Q3 2024
      Avg closing price $7.21
      Price range $5.48 - $8.83
      Increased shares by 14.7% (+305k shares) Q2 2024
      Avg closing price $6.42
      Price range $5.53 - $7.28
      Increased shares by 46.1% (+655k shares) Q1 2024
      Avg closing price $9.13
      Price range $7.44 - $11.21
      Increased shares by 26.7% (+299k shares) Q4 2023
      Avg closing price $8.17
      Price range $6.71 - $10.16
      Increased shares by 86.3% (+519k shares) Q3 2023
      Avg closing price $11.94
      Price range $9.35 - $14.32
      Increased shares by 1.9% (+11.1k shares) Q2 2023
      Avg closing price $11.91
      Price range $9.86 - $13.12
      Increased shares by 25.2% (+119k shares) Q1 2023
      Avg closing price $12.75
      Price range $10.23 - $14.76
      Sold 0.2% shares (-910 shares) Q4 2022
      Avg closing price $9.65
      Price range $6.47 - $11.32
      Increased shares by 54.2% (+166k shares) Q3 2022
      Avg closing price $13.24
      Price range $9.30 - $18.27
      Increased shares by 12.8% (+34.7k shares) Q2 2022
      Avg closing price $17.05
      Price range $11.79 - $27.63
      Increased shares by 13.0% (+31.3k shares) Q1 2022
      Avg closing price $28.37
      Price range $20.67 - $40.33
      Increased shares by 3.1% (+7.34k shares) Q4 2021
      Avg closing price $45.57
      Price range $36.68 - $54.02
      Sold 0.0% shares (-106 shares) Q3 2021
      Avg closing price $54.54
      Price range $49.57 - $58.15
      Increased shares by 5.0% (+11k shares) Q2 2021
      Avg closing price $53.27
      Price range $47.17 - $58.64
      Increased shares by 120.0% (+121k shares) Q1 2021
      Avg closing price $48.44
      Price range $42.51 - $54.07
      Increased shares by 55.5% (+36k shares) Q4 2020
      Avg closing price $36.89
      Price range $31.90 - $44.89
      Increased shares by 44.5% (+20k shares) Q3 2020
      Avg closing price $33.96
      Price range $28.55 - $36.91

      News about Health Catalyst Inc and PRIMECAP Management

      Brendel Financial Advisors LLC Makes New Investment in Health Catalyst, Inc. (NASDAQ:HCAT)

      Brendel Financial Advisors LLC Makes New Investment in Health Catalyst, Inc. (NASDAQ:HCAT)

      ¡­ funds and other institutional investors also recently modified their ¡­ worth $26,000. WealthPlan Investment Management LLC acquired a new ¡­ during the peri...

      EIN News Investing EIN News Investing, almost 2 years ago
      eVisit closes USD45m in Series B funding round led by Goldman Sachs Asset Management

      eVisit closes USD45m in Series B funding round led by Goldman Sachs Asset Management

      eVisit closes USD45m in Series B funding round led by Goldman Sachs Asset Management Submitted 22/09/2021 - 9:41am eVisit, a Virtual Care platform for large ...

      Private Equity Wire Private Equity Wire, almost 4 years ago
      VitalCDM? Ranked #1 in KLAS Revenue Cycle, Chargemaster Management Category for Third Year in a Row

      VitalCDM? Ranked #1 in KLAS Revenue Cycle, Chargemaster Management Category for Third Year in a Row

      SALT LAKE CITY, Feb. 2, 2021 /PRNewswire/ -- Vitalware by Health Catalyst today announced that its chargemaster management solution, VitalCDM, ranked number ...

      PR Newswire PR Newswire, over 4 years ago
      Patient Safety And Risk Management Software Market 2029 Emerging Trend and Global Demand - Health Catalyst (U.S.), LLC, Riskonnect Inc., Origami Risk

      Patient Safety And Risk Management Software Market 2029 Emerging Trend and Global Demand - Health Catalyst (U.S.), LLC, Riskonnect Inc., Origami Risk

      Global Patient Safety And Risk Management Software Market: Overview Increased instances of medical errors together with growing inclination among healthcare ...

      OpenPR OpenPR, almost 5 years ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×